Allergan plc (NYSE:AGN) saw a large increase in short interest in May. As of May 31st, there was short interest totalling 5,340,700 shares, an increase of 43.9% from the April 30th total of 3,712,500 shares. Based on an average daily trading volume, of 2,340,000 shares, the short-interest ratio is currently 2.3 days. Currently, 1.6% of the shares of the stock are sold short.
A number of institutional investors have recently bought and sold shares of the business. Patriot Financial Group Insurance Agency LLC grew its holdings in shares of Allergan by 2,162.5% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 181 shares of the company’s stock worth $27,000 after purchasing an additional 173 shares during the last quarter. Legacy Bridge LLC purchased a new position in shares of Allergan during the first quarter worth about $27,000. Liberty Wealth Management LLC grew its holdings in shares of Allergan by 108.8% during the first quarter. Liberty Wealth Management LLC now owns 190 shares of the company’s stock worth $27,000 after purchasing an additional 99 shares during the last quarter. Investors Research Corp purchased a new position in shares of Allergan during the first quarter worth about $29,000. Finally, Community Bank N.A. grew its holdings in shares of Allergan by 186.3% during the first quarter. Community Bank N.A. now owns 209 shares of the company’s stock worth $31,000 after purchasing an additional 136 shares during the last quarter. Institutional investors own 80.15% of the company’s stock.
A number of equities research analysts have recently issued reports on the company. ValuEngine upgraded Allergan from a “strong sell” rating to a “sell” rating in a research report on Tuesday, May 7th. Royal Bank of Canada dropped their price target on Allergan from $165.00 to $140.00 and set a “sector perform” rating for the company in a research report on Wednesday, May 8th. UBS Group dropped their price target on Allergan from $173.00 to $172.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Cantor Fitzgerald dropped their price target on Allergan from $180.00 to $125.00 and set a “neutral” rating for the company in a research report on Wednesday, June 12th. Finally, Mizuho restated a “buy” rating and issued a $194.00 price target on shares of Allergan in a research report on Wednesday, April 24th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $175.30.
Allergan stock traded up $0.72 during mid-day trading on Monday, hitting $116.64. The company’s stock had a trading volume of 200,399 shares, compared to its average volume of 2,777,444. The firm has a market cap of $37.98 billion, a price-to-earnings ratio of 6.99, a PEG ratio of 1.06 and a beta of 1.39. Allergan has a 1 year low of $115.19 and a 1 year high of $197.00. The company has a quick ratio of 0.60, a current ratio of 0.71 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average price of $135.02.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $3.79 earnings per share for the quarter, topping the consensus estimate of $3.55 by $0.24. The company had revenue of $3.60 billion during the quarter, compared to analyst estimates of $3.55 billion. Allergan had a positive return on equity of 8.45% and a negative net margin of 45.94%. The firm’s revenue for the quarter was down 2.0% compared to the same quarter last year. During the same period in the prior year, the business posted $3.74 earnings per share. As a group, analysts predict that Allergan will post 16.68 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Tuesday, May 14th were given a $0.74 dividend. The ex-dividend date of this dividend was Monday, May 13th. This represents a $2.96 annualized dividend and a yield of 2.54%. Allergan’s payout ratio is 17.74%.
COPYRIGHT VIOLATION NOTICE: This report was posted by Highlight Press and is the sole property of of Highlight Press. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://highlightpress.com/2019/06/17/allergan-plc-nyseagn-short-interest-up-43-9-in-may.html.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Further Reading: NASDAQ Stock Market Explained
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.